Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Verigen Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods, including medicines, medical devices, and blood products, to ensure their quality, safety, and efficacy. This Act provides a comprehensive framework for the oversight of therapeutic goods, including the licensing of manufacturers and the regulation of their activities. The revocation of a manufacturer's licence, as exemplified by the case of VeriGen Australia Pty Ltd, highlights the enforcement mechanisms within the Act to maintain high standards in the manufacture of therapeutic goods. The revocation was carried out under the authority granted by the Secretary, as delegated to Bill Turner, to enforce compliance with the Act’s stringent requirements. This action underscores the policy objective of safeguarding public health by removing entities that fail to meet the legislative standards from the supply chain of therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 pertains to the regulation of therapeutic goods within Australia, impacting various entities including manufacturers, importers, and suppliers. This Act applies to all therapeutic goods, which encompass a broad range of products such as medicines, medical devices, blood, and tissues. The legislation governs the entire supply chain of therapeutic goods, from manufacturing and importing to advertising and distribution, ensuring that these goods meet safety, quality, and efficacy standards. The Act's jurisdictional reach is national, applying across all states and territories of Australia, with the Commonwealth having overarching regulatory authority. The Act can impose revocation of manufacturing licenses upon certain conditions, such as at the request of the manufacturer, as demonstrated by the case of VeriGen Australia Pty Ltd, where Licence No. MI-2012-LI-02551-3 was revoked under paragraph 41(1)(d) of the Act. The revocation process is executed by the Secretary or their delegate, as evidenced by the notice signed by Bill Turner on 25 September 2012. The Act also provides for the publication of such revocations to maintain transparency and public awareness. Certain exclusions and exemptions may apply, with specific thresholds and conditions often defined through subordinate legislation, further detailing the scope and application of the Act.

Key Provisions

The Therapeutic Goods Act 1989, specifically section 41, outlines the circumstances under which a licence to manufacture therapeutic goods can be revoked (s 41(1)(d)). In this instance, the Secretary has exercised the power to revoke the licence held by VeriGen Australia Pty Ltd, identified by the licence number MI-2012-LI-02551-3. The revocation notice was published in writing by Bill Turner, who is acting as a delegate of the Secretary for this purpose (s 41). The company, located at C/- Hollywood Private Hospital, Monash Avenue, Nedlands, WA, 6009, had requested this action. Under the Therapeutic Goods Act 1989, the Act imposes certain obligations on entities holding licences to manufacture therapeutic goods. These obligations include compliance with all relevant legislative and regulatory requirements, adherence to good manufacturing practices, and ensuring that the therapeutic goods produced meet the standards set out in the Act. The revocation of a licence signifies that the Secretary has determined that the entity has failed to meet these obligations, or there are other grounds warranting such action. In this case, the revocation of VeriGen Australia Pty Ltd's licence likely resulted from a failure to comply with the statutory requirements or other regulatory breaches. The Therapeutic Goods Act 1989 also includes provisions for offences and penalties in the event of non-compliance with the Act. Offences under the Act can range from minor infringements to serious breaches, each carrying different consequences. For instance, knowingly supplying therapeutic goods that do not comply with the standards can result in substantial penalties. While the specific offences and penalties are detailed in other sections of the Act, it is clear that failure to comply with the Act's requirements can lead to civil or criminal proceedings. The maximum penalties for offences can include fines and imprisonment, depending on the severity of the breach. The revocation of VeriGen Australia Pty Ltd’s licence is a significant step, indicating a serious breach of the obligations placed upon the entity by the Act.